TGM2 and cranioectodermal dysplasia: Serum anti-TG2 IgA binding to the TG2 RE mutant significantly diminished compared with the binding to the wild-type TG2 (Figure 6B), indicating that the majority of the autoantibodies produced by manifest CeD patients target the epitope 2 surface of human TG2, and/or that their binding is reduced by alterations of the TG2 structure by the mutations.